Blueprint Medicines (BPMC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Blueprint Medicines (BPMC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 30, 2024, to report its third quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 387547. A webcast of the call will also be available under "Events and Presentations" ...

CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET. TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET. A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http:/ ...

A downtrend has been apparent in Blueprint Medicines (BPMC) lately. While the stock has lost 8.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...

Blueprint Medicines Corporation (BPMC) reported second-quarter 2024 adjusted loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.28. The company had reported a loss of $2.19 per share in the year-ago quarter. Quarterly revenues of $138.2 million surpassed the Zacks Consensus Estimate of $105 million. Total revenues jumped almost 140% year over year. Despite the better-than-expected results, shares of Blueprint Medicines were down 7.4% on Aug 1 following the earnings announ ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Salveen Richter - Goldman Sachs Brad Canino - Stifel Marc Frahm - TD Cowen Michael Schmidt - Guggen ...

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Regi ...

Second Quarter 2024 Financial Results AUG 1, 2024 Agenda INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer CORPORATE PROGRESS Christy Rossi Chief Operating Officer | --- | --- | --- | |-------|-------------------------|-------| | | | | | | | | | | | | | | Q2 2024 FINANCIAL | | | | PERFORMANCE | | | | | | | | Mike Landsittel | | | | Chief Financial Officer | | Not for promotional use 2 Forward-looking statements 3 This presentation contains forwa ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $2.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this cancer drug developer would post a loss of $1.64 per share when it actually produced a loss of $1.32, delivering a surprise of 19.51%. Over the last four quarters, the ...